4D Medicine, a Nottingham, UK-based company developing biomaterials for 3D printed implants and surgical devices, raised $3.4M in Series A funding.
The round was led by Oshen Holdings and backed by DSW Ventures, SFC Capital, Boundary Capital and private investors including scientists and surgeons.
The company intends to use the funds to complete pre-clinical testing of its first product range and seek FDA clearance for entry into the US market.
Led by CEO Philip Smith, 4D Medicine is a spin-out of the Universities of Birmingham and Warwick and has developed a resorbable biomaterial, 4Degra, that is being used to develop implants such as orthopaedic devices or soft tissue scaffolds to help patients recovering from surgery or injuries. Preliminary testing has shown that as healing progresses, the biomaterial gradually erodes and is resorbed by normal metabolic processes as natural tissue grows back in its place.
FinSMEs
25/07/2024